Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Successful treatment of primary malignant lymphoma of the penis by organ-preserving rituximab-containing chemotherapy.

Literature DB >> 21710157

Successful treatment of primary malignant lymphoma of the penis by organ-preserving rituximab-containing chemotherapy.

Shuzo Hamamoto¹, Keiichi Tozawa, Hideki Nishio, Noriyasu Kawai, Kenjiro Kohri.

Abstract

Primary penile lymphoma is extremely rare. Here we report the case of a 67-year-old man with the chief complaints of difficulty in urination and priapism, who was eventually diagnosed with primary malignant lymphoma of the penis. Pathological examination of excision biopsy of the left inguinal lymph node revealed malignant CD20+ diffuse large B-cell lymphoma. We treated this patient with a systemic rituximab-chemotherapy regimen and obtained good results, in terms of both functional and cosmetic outcomes. Soluble interleukin-2 receptor was a useful tumor marker for evaluating the therapeutic effect. The patient has been in remission for 10 months after the discontinuation of chemotherapy.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21710157 DOI： 10.1007/s10147-011-0273-8

Source DB: PubMed Journal: Int J Clin Oncol ISSN： 1341-9625 Impact factor: 3.402

13 in total

1. Primary lymphoma of the penis: diagnosis and treatment.

Authors: F Arena; C di Stefano; G Peracchia; A Barbieri; P Cortellini
Journal: Eur Urol Date: 2001-02 Impact factor: 20.096

2. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Authors: Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning
Journal: J Clin Oncol Date: 2006-06-05 Impact factor: 44.544

3. Long standing priapism as presentation of lymphoma.

Authors: Ralph Madeb; Ronen Rub; Nahum Erlich; Paul K Hegarty; Daniel Yachia
Journal: Am J Hematol Date: 2007-01 Impact factor: 10.047

4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors: Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal: N Engl J Med Date: 2002-01-24 Impact factor: 91.245

5. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors: R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal: N Engl J Med Date: 1993-04-08 Impact factor: 91.245

6. Cloning of the gamma chain of the human IL-2 receptor.

Authors: T Takeshita; H Asao; K Ohtani; N Ishii; S Kumaki; N Tanaka; H Munakata; M Nakamura; K Sugamura
Journal: Science Date: 1992-07-17 Impact factor: 47.728

7. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.

Authors: Hideko Goto; Hisashi Tsurumi; Masao Takemura; Yoriko Ino-Shimomura; Senji Kasahara; Michio Sawada; Toshiki Yamada; Takeshi Hara; Kenji Fukuno; Naoe Goto; Masataka Okuno; Tsuyoshi Takami; Mitsuru Seishima; Hisataka Moriwaki
Journal: J Cancer Res Clin Oncol Date: 2004-10-21 Impact factor: 4.553

8. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.

Authors: D Ennishi; M Yokoyama; Y Terui; H Asai; S Sakajiri; Y Mishima; S Takahashi; H Komatsu; K Ikeda; K Takeuchi; M Tanimoto; K Hatake
Journal: Ann Oncol Date: 2008-12-12 Impact factor: 32.976

Successful treatment of primary malignant lymphoma of the penis by organ-preserving rituximab-containing chemotherapy.

1. Primary lymphoma of the penis: diagnosis and treatment.

2. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

3. Long standing priapism as presentation of lymphoma.

4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

5. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

6. Cloning of the gamma chain of the human IL-2 receptor.

7. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.

8. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.

9. Primary lymphoma of the penis.

10. Progressive painless swelling of glans penis: uncommon clinical manifestation of systemic non-Hodgkin's lymphoma.

1. Malignant priapism secondary to isolated penile metastasis from a renal pelvic carcinoma.

2. Lymphoma presenting as cancer of the glans penis: a case report.

3. Conservative Therapy in Two Cases of Non-Hodgkin Lymphoma of the Penis: Case Reports With Review of the Literature.

4. Primary Non-Hodgkin's Lymphoma of Penis Masquerading as a Non-Healing Ulcer in the Penile Shaft.

5. Priapism as the initial symptom of primary penile lymphoma: A case report.